Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Operating Leases (2022 - 2025)

Terns Pharmaceuticals filings provide 4 years of Operating Leases readings, the most recent being $445000.0 for Q4 2025.

  • Quarterly Operating Leases fell 51.58% to $445000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $445000.0 through Dec 2025, down 51.58% year-over-year, with the annual reading at $445000.0 for FY2025, 51.58% down from the prior year.
  • Operating Leases hit $445000.0 in Q4 2025 for Terns Pharmaceuticals, down from $570000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $1.1 million in Q2 2025 and bottomed at $63000.0 in Q3 2023.
  • Average Operating Leases over 4 years is $667307.7, with a median of $702000.0 recorded in 2022.
  • The largest annual shift saw Operating Leases plummeted 91.03% in 2023 before it skyrocketed 1539.68% in 2024.
  • Terns Pharmaceuticals' Operating Leases stood at $544000.0 in 2022, then crashed by 88.42% to $63000.0 in 2023, then soared by 1358.73% to $919000.0 in 2024, then crashed by 51.58% to $445000.0 in 2025.
  • Per Business Quant, the three most recent readings for TERN's Operating Leases are $445000.0 (Q4 2025), $570000.0 (Q3 2025), and $1.1 million (Q2 2025).